340 related articles for article (PubMed ID: 27815357)
21. Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.
Amaki-Takao M; Yamaguchi T; Natsume S; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Miyaki M
Oncology; 2016; 91(3):162-70. PubMed ID: 27404270
[TBL] [Abstract][Full Text] [Related]
22. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.
Guo F; Gong H; Zhao H; Chen J; Zhang Y; Zhang L; Shi X; Zhang A; Jin H; Zhang J; He Y
Sci Rep; 2018 Apr; 8(1):6076. PubMed ID: 29666387
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
25.
El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Bajjou T; Sekhsokh Y; Benmokhtar S; Jafari M; Baba W; Oukabli M; El Annaz H; Abi R; Tagajdid MR; El Kochri S; Lahlou IA; Ameziane El Hassani R; Ennibi K
Cancer Control; 2024; 31():10732748241262179. PubMed ID: 38875469
[TBL] [Abstract][Full Text] [Related]
26. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.
Mouradov D; Domingo E; Gibbs P; Jorissen RN; Li S; Soo PY; Lipton L; Desai J; Danielsen HE; Oukrif D; Novelli M; Yau C; Holmes CC; Jones IT; McLaughlin S; Molloy P; Hawkins NJ; Ward R; Midgely R; Kerr D; Tomlinson IP; Sieber OM
Am J Gastroenterol; 2013 Nov; 108(11):1785-93. PubMed ID: 24042191
[TBL] [Abstract][Full Text] [Related]
27. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
28. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.
El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L
PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337
[TBL] [Abstract][Full Text] [Related]
29. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
[TBL] [Abstract][Full Text] [Related]
30.
Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
[No Abstract] [Full Text] [Related]
31. Clinical validation of coexisting driver mutations in colorectal cancers.
Zheng G; Tseng LH; Haley L; Ibrahim J; Bynum J; Xian R; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2019 Apr; 86():12-20. PubMed ID: 30481508
[TBL] [Abstract][Full Text] [Related]
32. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
33. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
[TBL] [Abstract][Full Text] [Related]
34. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
35. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
[TBL] [Abstract][Full Text] [Related]
36. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
[TBL] [Abstract][Full Text] [Related]
37. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
38. KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study.
Sanchez-Ibarra HE; Jiang X; Gallegos-Gonzalez EY; Cavazos-González AC; Chen Y; Morcos F; Barrera-Saldaña HA
PLoS One; 2020; 15(7):e0235490. PubMed ID: 32628708
[TBL] [Abstract][Full Text] [Related]
39. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
40. Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
Yanus GA; Belyaeva AV; Ivantsov AO; Kuligina ESh; Suspitsin EN; Mitiushkina NV; Aleksakhina SN; Iyevleva AG; Zaitseva OA; Yatsuk OS; Gorodnova TV; Strelkova TN; Efremova SA; Lepenchuk AY; Ochir-Garyaev AN; Paneyah MB; Matsko DE; Togo AV; Imyanitov EN
Med Oncol; 2013; 30(3):686. PubMed ID: 23943423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]